Everand Logo

Welcome to Everand!

  • Discover this podcast and so much more

    Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

    Zepbound vs Wegovy: A two horse race

    Zepbound vs Wegovy: A two horse race

    FromBioSpace

    Start listeningView podcast show

    Zepbound vs Wegovy: A two horse race

    FromBioSpace

    ratings:
    Length:
    14 minutes
    Released:
    Nov 15, 2023
    Format:
    Podcast episode

    Description

    Last week, the FDA approved Eli Lilly's obesity drug Zepbound, creating an anticipated intense competition between it and Novo Nordisk's Wegovy. BioSpace's Greg Slabodkin, Tyler Patchen and Lori Ellis discuss the weight loss race and the future of this drug class.
    Plus, a quick recap on Valneva, the FDA's first Chikungunya vaccine approval.
    Released:
    Nov 15, 2023
    Format:
    Podcast episode

    Titles in the series (45)

    Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.